MedTrace Logo

Investigating the Adjunctive Use of Mirabegron in the Early Post-Rezum Procedure Period

NCT07017439 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-06-12

No results posted yet for this study

Summary

The investigators propose conducting a randomized controlled trial at the Men's Health Clinic to evaluate whether patients who start and continue mirabegron postoperatively after undergoing Rezum therapy experience enhanced patient-reported outcomes, improved quality of life (QoL), and comparable rates of adverse events. There are no predicted adverse events of this study. There are no identified potential harms of this study.

Conditions

  • Benign Prostate Hypertrophy(BPH)

Interventions

DRUG

Beta-3 agonists (Mirabegron/Myrbetriq)

Patients in this arm will receive the medication in pill form following their procedure

OTHER

Placebo group post rezum

Patients in this arm will receive the placebo pill following their procedure.

Sponsors & Collaborators

  • University of Manitoba

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-08-31
Primary Completion
2025-12-31
Completion
2026-06-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07017439 on ClinicalTrials.gov